Aripiprazole IM Depot for Chinese Patients With Schizophrenia
Status:
Completed
Trial end date:
2019-11-08
Target enrollment:
Participant gender:
Summary
This study assess pharmacokinetics and safety of single-administration of Aripiprazole IM
Depot formulation at doses of 300 and 400mg in patients with schizophrenia.